Загрузка...
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
BACKGROUND/AIMS: Data on the efficacy and safety of the adalimumab biosimilar Exemptia are limited. METHODS: Patients with moderate-to-severe active steroid-refractory ulcerative colitis (UC) treated at Dayanand Medical College and Hospital, India were offered cyclosporine A, biologicals or biosimil...
Сохранить в:
| Опубликовано в: : | Intest Res |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Korean Association for the Study of Intestinal Diseases
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5797276/ https://ncbi.nlm.nih.gov/pubmed/29422802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5217/ir.2018.16.1.83 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|